The journal and Authors retract the 23 April 2021 article cited above for the following reason as provided by the Authors:
Following publication, the Authors were informed that they were not entitled to publish the raw data underlying the findings by the supplier of the analyzed drug.
Therefore, with the agreement of the Authors and the Chief Editor of the Oral Cancers specialty of Frontiers in Oral Health, the publication is being retracted.
Summary
Keywords
oral squamous cell carcinoma, Pembrolizumab, Tumor microenviroment, Immune reaction, cancer-associate fibroblasts
Citation
Frontiers Editorial Office (2022) Retraction: Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings. Front. Oral. Health 3:893486. doi: 10.3389/froh.2022.893486
Received
10 March 2022
Accepted
10 March 2022
Published
22 March 2022
Approved by
Ricardo D. Coletta, Campinas State University, Brazil
Volume
3 - 2022
Updates
Copyright
© 2022 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office editorial.office@frontiersin.org
This article was submitted to Oral Cancers, a section of the journal Frontiers in Oral Health
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.